Sandoz and Momenta to pay $120m to end antitrust suit

Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novartis scores UK win in high-stakes Entresto fight

14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.

Pharma

Lilly mounts defence as generics circle Mounjaro and Zepbound

11 August 2026 A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.

Pharma

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

10 August 2026 Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.

More features

Novartis scores UK win in high-stakes Entresto fight

Invisalign maker secures first China win against clear aligner rival

Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

Lilly mounts defence as generics circle Mounjaro and Zepbound

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

Kirkland clears conflicts hurdle in trade secrets spat

Sandoz and Momenta to pay $120m to end antitrust suit

More on this story

Editor's picks

Editor's picks

More features